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Abstract
Background: Hemoglobin E is an important hemoglobin variant with a worldwide distribution. A number of
hemoglobinopathies have been reported from Pakistan. However a comprehensive description of hemoglobin E
syndromes for the country was never made. This study aimed to describe various hemoglobin E disorders based
on hematological parameters and chromatography. The sub-aim was to characterize hemoglobin E at molecular
level.
Methods: This was a hospital based study conducted prospectively for a period of one year extending from
January 1 to December 31, 2008. EDTA blood samples were analyzed for completed blood counts and hemoglobin
variants through automated hematology analyzer and Bio-Rad beta thalassaemia short program respectively. Six
samples were randomly selected to characterize HbE at molecular level through RFLP-PCR utilizing MnlI restriction
enzyme.
Results: During the study period, 11403 chromatograms were analyzed and Hb E was detected in 41 (or 0.36%)
samples. Different hemoglobin E syndromes identified were HbEA (n = 20 or 49%), HbE/b-thalassemia (n = 14 or
34%), HbEE (n = 6 or 15%) and HbE/HbS (n = 1 or 2%). Compound heterozygosity for HbE and beta thalassaemia
was found to be the most severely affected phenotype. RFLP-PCR utilizing MnlI successfully characterized HbE at
molecular level in six randomly selected samples.
Conclusions: Various HbE phenotypes are prevalent in Pakistan with HbEA and HbE/b thalassaemia representing
the most common syndromes. Chromatography cannot only successfully identify hemoglobin E but also assist in
further characterization into its phenotype including compound heterozygosity. Definitive diagnosis of HbE can
easily be achieved through RFLP-PCR.
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Background
Hemoglobin E is an important and common b-globin
chain variant resulting from substitution of glutamine
by lysine at codon 26 of b-globin gene (∞2b2
26Glu®Lys).
Since its first description by Chernoff and his colleagues
in 1954 [1], HbE was increasingly reported from several
parts of the world. Hb E confers a survival advantage
against Plasmodium falciparum and could be the logical
explanation for its high global prevalence [2]. It is the
most prevalent abnormal hemoglobin in South East Asia
with its frequency approaching 60% in Northeast regions
of Thailand [3,4], Laos and Cambodia [5]. Significant
numbers were reported from other Asian countries such
as Sri Lanka [6], North Eastern India [7], Bangladesh
[8], Nepal [6], Vietnam [9] and Malaysia [10]. Addition-
ally, population transmigration led to its emergence in
United States [11] and Canada [5].
Hb E occurs both in homozygous (EE) and heterozy-
gous (EA or E trait) states and may co-inherits with
alpha [12] and beta thalassaemia [13], HbS, HbC and
other hemoglobin variants [6]. Hb EE and E trait are
mild disorders and are associated with either mild or no
anemia. In contrast, HbE/beta thalassaemia displayed a
remarkable variability in its clinical severity varying
from mildly asymptomatic state to a severe transfusion
dependent anemia [14]. HbE/HbS results in a sickle cell
disorder similar to sickle/beta + thalassaemia [14].
It is important to diagnose Hb E disorders correctly as
the clinical course is variable for various phenotypes and
would modify the management. A cost effective and
simple combination of hemoglobin instability and osmo-
tic fragility tests was devised for detection of Hb E in
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include hemoglobin electrophoresis where Hb E runs
with the same speed as Hb A2 on alkaline pH requiring
subsequent identification on acidic pH. On high perfor-
mance liquid chromatography (HPLC), Hb E has the
same retention time as HbA2 [16] but is identified
because of its quantity which is substantial in compari-
son to HbA2. Ultimate diagnosis of this variant rests on
molecular analysis. RFLP-PCR [17], DNA sequencing
and allelic discrimination analysis [18]are successfully
used for molecular characterization of hemoglobin E.
Situated in South Asia, Pakistan is a home to 180 mil-
lion people. Various hemoglobinopathies have been
reported from this country [19] including alpha [20] and
beta thalassaemia [21,22], sickle cell disorders [23], Hb
D [24,25], Hb Q [26]and other rare variants [27]. Spora-
dic cases of HbE have been reported from Pakistanis liv-
ing in United Kingdom [6,28] but the information
regarding HbE for the country remains fragmentary
hitherto. Since Pakistan showed a high incidence of beta
thalassaemia major [22,29], high estimates for HbE/b-
thalassaemia syndromes were expected. Further to this
credence, there was a need to characterize HbE in the
large and diverse population of the country in order to
ensure optimal patient management. The present hospi-
tal based study was focused on the identification of Hb
E through HPLC and on stratification of its various phe-
notypes based on hematological parameters. No attempt
was made to analyze other hemoglobinopathies as a
number of previous studies had already addressed this




We prospectively analyzed blood samples during one
year from January 1 to December31, 2008 in the clinical
laboratory of The Aga Khan University, Pakistan. The
patients were referred by various physicians from within
and outside the hospital for the work up of anemia,
antenatal and pre-marital screening. The laboratory
served as a referral laboratory for the country and sam-
ples were obtained from 94 blood collection centers
within the city and 82 similar centers from the entire
country. Clinical details were assessed based on informa-
tion provided by the requesting physicians.
Complete blood counts and chromatographic analysis of
hemoglobin variants
Briefly, we collected five milliliters of blood from each
patient in ethylene di-amine tetra acetate micro cuvettes
(BD, Becton Dickinson and Company, New Jersey,
USA). The samples were received cooled at 4°C by fast
transportation in our lab and were analyzed within 24 h.
Hemogram was performed on each sample by Coulter
G e n - S( C o u l t e rE l e c t r o n i c s ,F u l l e r t o n ,C A ,U S A ) ,a n d
peripheral film stained with Leishman’ss t a i nw a se x a m -
ined by experienced technologists and hematologists.
We used the Bio-Rad Variant Classic b Thalassaemia
Short program (Bio-Rad Laboratories Inc. Hercules, CA,
and USA) for the hemoglobin quantification. This auto-
mated system utilizes the principle of cation exchange
HPLC with detection at double wavelength (415 and
690 nm). The instrument is user friendly and analyzed
each sample for a period of 5-6 min., with various posi-
tively charged hemoglobin molecules eluting at different
times depending on their affinity for anion-coated resin
columns. We use a retention time (RT) of 3.65 to 3.7
min to identify Hb E + Hb A2 as the two co-elute in the
same A2window [16].
Molecular analysis
In mutational analysis, we prospectively selected 6 sam-
ples which were screened as Hb E trait (n = 2) and Hb
E/beta thalassaemia (n = 4) on HPLC. Total genomic
DNA was isolated from peripheral white cells according
to manufacturer’si n s t r u c t i o n su s i n gW i z a r d
® Genomic
DNA Purification kit (Promega USA Cat No: A1125).
RFLP-PCR based approach was used for detecting b26
G ® A mutation utilizing enzyme MnlI[ 3 0 ] .H bE
mutation destroys a cleavage site for MnlI which cleaves
DNA at the sequence 3’-GAGG-5’ [31]. The schematic
representation of beta gene with primers and sequence
amplified along with cut base pair sizes are detailed in
Figure 1. PCR amplification was performed using 1 μg
of genomic DNA in 25 μl reaction optimized by using
the following concentrations: 5 × buffer 5 μl, MgCl2 1.5
5´-CCTGAGGAGAAGTCTGCCGTT-3´
Exon I IVS-1 Exon 2 IVS-2      Exon3
5´-CATCACTAAAGGCACGCACT-3´
Digested products of ȕA
Digested products of ȕE
57bp 171bp 106bp                
106bp 228 bp
MnlI 123456789
Figure 1 Schematic representation of b-g l o b i ng e n ea n d
sequence amplified by forward primer (red) and reverse
primer (green) and the cut DNA in b
A and b
E globin gene
subsequent to digestion with restriction enzyme MnlI (red thin
arrow).
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reconstituted with 14 μl of water. Eppendorf
®Master
Cycler gradient (Germany) using annealing temperatures
calculated according to Tm of primer pairs run at 34
cycles with a further 7 min extension at 72°C. Amplified
products were digested with 5 units of MnlIa n ds e p a -
rated through electrophoresis on 1.5% agarose gel.
These were visualized under UV light after ethidium
bromide staining.
Statistical analysis
The data was entered into SPSS version 16(SPSS Inc.,
Chicago, IL, USA) to compute descriptive data. Various
hemoglobin E phenotypes were identified with respect
to hemoglobin, red cell indices and hemoglobin variants
(HbE + HbA2, Hb F, HbA or any other variant) as
described in literature [6,14,18].
Ethical issues
The study was approved by institutional ethical review
c o m m i t t e eo fT h eA g aK h a nU n i v e r s i t y( E R Ca p p r o v a l
#1600-P80-ERC-2010). The retrieved computerized data
from laboratory was re-coded to maintain anonymity.
The samples were collected from patients after their
informed consent.
Results
We reviewed 11403 chromatograms in the year 2008
identifying 1944 (17%) samples with hemoglobin var-
iants. The hemoglobinopathies detected were as follows:
b -thalassaemia trait, b -thalassaemia major, Hb S disor-
ders, Hb D and Hb Q in 1174 (60%), 274(14%),246
(13%),193 (10%) and 7(0.4%) samples respectively. One
case of Hb C and Hb H each were identified. Another
48 cases (2% of abnormal variants or 0.4% of total ana-
lyzed samples) were observed having the retention time
of 3.65 to 3.7 min and were preliminary labeled as
Hemoglobin E. There were seven samples with 38-48%
of abnormal hemoglobin where the possibility of Hb D
Iran could not be excluded. These were excluded from
final analysis leaving a total of 41 cases for evaluation of
Hb E.
Subjects characteristics
The mean age (± SD) was 13.6 years (± 11.3) ranging
from 4 months to 38 years. There were 23 males and 18
females. Clinical details were available for some of the
patients and hence were discussed where obtainable.
Hematological analysis
1. Hb E Trait
This constituted the largest diagnosed group compris-
ing of 48.8% (n = 20). There were 10 males and an
equal number of females with a median age of 14.0 ±
12.8 years. Thirteen children and seven adults were
diagnosed. Hemoglobin E ranged from 16.4 to 30.6%
(mean ± SD; 25.9 ± 4.3). Six patients showed high HbF
ranging from 4.1 to 8.6%. Only six (30%) subjects (four
females and two males) had hemoglobin within refer-
ence range. Remaining 14 patients had lower mean
hemoglobin, MCV and MCH [8.6 ± 2.4 g/dl, 65.5 ±
9.1 fl and 21.2 ± 3.4 pg respectively] as well as hypo-
chromic microcytic red cells with anisocytosis. Three
patients had severe anemia with hemoglobin less than
7.0 g/dl.
2. b-thalassaemia/HbE
Fourteen (34%) cases (10 females and 4 males with med-
ian age of 9.3 ± 7.3 years) were diagnosed as compound
heterozygotes for HbE and b- thalassaemia. None of the
patient in this group showed hemoglobin above 8 g/dl.
The mean MCV and MCH were 68.1 ± 9.3 fl and 21.0
± 3.3 pg respectively. Hb F was high in all patients ran-
ging from 16.3 to 64.7% while HbE was variable from
11.6 to 65.3%. Peripheral film review showed hypochro-
mic microcytic red cells in all cases with nucleated red
cells in twelve cases. No attempt was made to differenti-
ate HbE/b°a n dH b E / b + as samples were not analysed
for b-thalassemia mutations.
3. HbEE Homozygosity
Hemoglobin EE disorder was observed in six (14.6%)
patients (four males and two females with median age
of 24 ± 8 years). The criteria for diagnosis was a high
HbE (> 78%) and a low HbF (< 3%). The females (n =
4) had hemoglobin in the range of 9.6 to 10.6 g/dl. Two
males aged four and 25 years had hemoglobin of 7.6 g/
dl each. All subjects had hypochromic and microcytic
red cell indices. Only one patient had high HbF (8.5%)
then the set criteria. He was a 25 year old male with
hemoglobin of 7.6 g/dl. The possibility of co-existing a-
thalassaemia cannot be excluded in this patient.
4. HbE/Hb S
Compound heterozygosity for HbE and HbS was seen in
one case. This patient presented at the age of two years
with anemia and splenomegaly and had received only
one transfusion in the past two years. Hematological
parameters are given in Table 1.
Molecular analysis
Results of DNA analysis of six samples before and after
MnlI digestion are shown in Figure 2. The amplification
of gene produces a 334 bp product in wild and mutant
types (figure not shown). Subsequent to digestion three
fragments of 57, 106 and 171 bp were observed in wild
type and two fragments 106 and 228 bp products were
seen in mutant type. Two heterozygous subjects (b
A/b
E)
and four with compound heterozygosity for b thalassae-
mia/HbE showed four fragments of 57, 106, 171 and
228 bp.
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Hb E was detected in 0.4% of our samples. Our clinical
lab receives samples from the entire country hence the
population was well represented in the study. Since this
was a hospital based study, the observed frequency
might be an overestimation of the true incidence in gen-
eral population. However, our intention was to identify
and report HbE in Pakistani population and this study
served our purpose. Heterozygous AE represented the
commonest phenotype followed by b- thalassaemia/Hb
in Pakistan. Various HbE phenotypes were differentiated
through cation exchange chromatographic analysis and
successfully characterized at molecular level. For diagno-
s i so fH b E ,ar e t e n t i o nt i m eo f3 . 6 5 - 3 . 7m i nw a su s e d .
Besides HbE, several hemoglobin variants [HbA2,H b
Lepore, Hb D-Iran, HbG-Honolulu, Hb Korle-Bu] elute
in the A2 window(RT: 3.30-3.90) [16]. These can be suc-
cessfully differentiated on the basis of variance in their
quantities and RT [16]. Hence authors believe that HbE
was correctly identified as supported by the molecular
studies.
Clinically HbE is a mild type of disorder both in
homozygous and heterozygous states therefore Hb E
individuals are minimally anemic and asymptomatic [6].
However, co-inheritance of hemoglobin E and beta tha-
lassaemia trait results in b- thalassaemia/HbE disease
having variable phenotypes ranging from transfusion
dependence to a complete absence of symptoms [28].
This inconsistent expression is attributed to HbE
instability during fever and oxidative stress leading to
fall in hemoglobin concentration [32]. It is the common-
est form of severe thalassaemia in the world and is most
prevalent in South Asia. We observed that our subjects
with b- thalassaemia/HbE were mainly young children
(aged four months to 13 years) who presented with
severe hypochromic and microcytic anemia having tar-
get cells, basophilic stippling, fragmented red cells and
nucleated red cells. The young age at presentation
reflects the severity of anemia and hence early consulta-
tion. This was the most severely affected phenotype
observed and the patients in this group demonstrated
very low levels of hemoglobin. Since, b-thalassaemia is
widely prevalent in Pakistan with a carrier rate of 5%
[22]; this combination of HbE and b-thalassaemia was
not unexpected. We could not differentiate HbE/b° from
HbE/b + as samples were not analyzed for b-thalassemia
mutations. However, Rees DC studied 45 patients with
b- thalassaemia/HbE and showed that HbE/HbF ratio
was significantly higher (3.1) in patients with regular
transfusions in contrast to 1.8 in un-transfused patients.
This reflected the relative reduction in g-globin chain
synthesis subsequent to blood transfusions. HbE/HbF
ratio in 12 of the patients in our study ranged from 0.27
to 2.0 (mean ± 1SD; 1.4 ± 0.98) showing infrequent
blood transfusions. Two patients had higher ratios 2.65
and 4.0 but both of them were on regular blood
transfusions.
Subjects with hemoglobin E trait were mostly young
adults and the reasons for their testing were extended
family screening or investigation of hypochromic micro-
cytic red cells on routine CBC. Females were evaluated
as a work up of their antenatal screening. Contrary to
usual finding of mild or no anemia in hemoglobin AE,
14 subjects (70%) presented with hypochromic and
microcytic anemia including three patients with severe
anemia (< 7 g/dl). Two possible explanations were either
the presence of iron deficiency anemia or concomitant
occurrence of a- thalassaemia. Iron deficiency is
Table 1 Hematological features of various hemoglobin E phenotypes (n = 41)
Phenotype n Hb (g/dl) MCV (fl) MCH (pg) HbA (%) HbE + A2 (%) Hb (F %) Others (%)
EE 6 8.8 ± 1.6 56.9 ± 4.1 17.4 ± 1.8 0 81.7 ± 1.9 2.4 ± 3.3 -
EA 20 9.7 ± 2.6 67.3 ± 8.1 21.9 ± 3.1 72.3 ± 4.3 25.9 ± 4.3 2.1 ± 3.4 -
E/b-thalassaemia 14 5.0 ± 1.8 68.1 ± 9.3 21.0 ± 3.3 19.9 ± 16.0 43.7 ± 16.3 36.3 ± 13.8 -
E/S 1 7.6 67.6 20.4 0 11.8 19.3 HbS = 68.9






Figure 2 Cut DNA subsequent to digestion with MnlI.M=
Molecular marker of 100 bp, lanes 1, 8, 9 = normal subjects; lane 2
and 3 = subjects heterozygous for HbE (b
A/b
E); lanes 4-7 = subjects
compound heterozygous for HbE and beta thalassaemia; lane 10 =
blank.
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reported prevalence rate of over 2% in the country [20].
In 1987, Katsanis E et al. studied 33 children with HbE
trait and observed co-existing anemia in 62% of them
having substantially lower hemoglobin levels and HbE%
than expected [5]. Unfortunately, iron studies and a-
thalassaemia tests were not available for our subjects.
Usually the carrier state demonstrates 20-30% of hemo-
globin E but we observed a lower range of 16-19% in
three cases. Authors believed that concomitant iron
deficiency or alpha thalassemia resulted in lowering of
Hb E [6].
Six cases with homozygous E were observed in the
study. Our criteria of diagnosis were HbE > 75% and <
3% hemoglobin F. It has been argued that HbEE and
HbE/beta thalassaemia are overlapping syndromes and
cannot be phenotyped correctly [18,36]. Correct diagno-
sis is the key to the optimum management. However,
our experience showed that HPLC can help in differen-
tiating the two as HbF and HbE levels were significantly
different in both phenotypes. Also, it is known that reg-
ular transfusions in HbE/beta thalassaemia may decrease
HbF levels but not HbE [28] which could further assist
in correct diagnosis.
We observed a single case of compound heterozygos-
ity for hemoglobin E/S. Hemoglobin S had been
reported from this region [23] and the occurrence of
this combination was no surprise. However, HbE and F
levels did not correspond to the previously published
reports in the similar condition. We hypothesized that
co-existing iron deficiency reduced the quantity of HbE
and high HbF in sickle cell disorders is not atypical for
this geographical region [23].
Strengths and limitations
This was the first report describing the various Hb E
phenotypes in Pakistan. The study was limited by patchy
clinical details, lack of iron studies and molecular confir-
mation of a and b- thalassaemia. Being a single hospital
based study; our data did not reflect the true prevalence
of Hb E in Pakistani population.
Conclusions
Various HbE phenotypes are prevalent in Pakistan with
HbEA and HbE/b thalassaemia representing the most
common syndromes. Chromatography cannot only suc-
cessfully identify hemoglobin E but also assist in further
characterization into its phenotype including compound
heterozygosity. Definitive diagnosis of HbE can easily be
achieved through RFLP-PCR.
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